Most solid tumors are characterized by a metabolic shift from glucose oxidation to glycolysis, in part due to actively suppressed mitochondrial function, a state that favors resistance to apoptosis. Suppressed mitochondrial function may also contribute to the activation of hypoxia-inducible factor 1a (HIF1a) and angiogenesis. We have previously shown that the inhibitor of pyruvate dehydrogenase kinase (PDK) dichloroacetate (DCA) activates glucose oxidation and induces apoptosis in cancer cells in vitro and in vivo. We hypothesized that DCA will also reverse the 'pseudohypoxic' mitochondrial signals that lead to HIF1a activation in cancer, even in the absence of hypoxia and inhibit cancer angiogenesis. We show that inhibition of PDKII inhibits HIF1a in cancer cells using several techniques, including HIF1a luciferase reporter assays. Using pharmacologic and molecular approaches that suppress the prolyl-hydroxylase (PHD)-mediated inhibition of HIF1a, we show that DCA inhibits HIF1a by both a PHD-dependent mechanism (that involves a DCA-induced increase in the production of mitochondria-derived a-ketoglutarate) and a PHDindependent mechanism, involving activation of p53 via mitochondrial-derived H 2 O 2 , as well as activation of GSK3b. Effective inhibition of HIF1a is shown by a decrease in the expression of several HIF1a regulated gene products as well as inhibition of angiogenesis in vitro in matrigel assays. More importantly, in rat xenotransplant models of non-small cell lung cancer and breast cancer, we show effective inhibition of angiogenesis and tumor perfusion in vivo, assessed by contrast-enhanced ultrasonography, nuclear imaging techniques and histology. This work suggests that mitochondria-targeting metabolic modulators that increase pyruvate dehydrogenase activity, in addition to the recently described pro-apoptotic and anti-proliferative effects, suppress angiogenesis as well, normalizing the pseudo-hypoxic signals that lead to normoxic HIF1a activation in solid tumors.
INTRODUCTION
Apoptosis resistance and angiogenesis are both critical for tumor progression but are often seen as separate, independent processes. An ideal cancer therapy would target both and be selective to cancer cells, sparing non-cancerous tissues. There is emerging evidence that reversing the unique metabolic remodeling of cancer (that is, a strong glycolytic phenotype, the Warburg effect) is a promising therapeutic strategy that may offer relative selectivity to cancer. [1] [2] [3] [4] [5] The suppressed mitochondrial function and decreased glucose oxidation (GO) in exchange for upregulated glycolysis, a much less efficient means of generating energy, may at first appear paradoxical for cancer. However, suppressing mitochondrial function can also lead to decreased mitochondria-driven apoptosis, and may allow important metabolites in the glycolytic pathway, including ribose sugars and nonessential amino acids to be shifted towards biosynthetic pathways that are needed in rapidly proliferating cells. 4, 6 Metabolic targeting of key enzymes that regulate the balance between GO (that exclusively occurs in mitochondria) and cytoplasmic glycolysis, including pyruvate dehydrogenase kinase (PDK), 7 lactate dehydrogenase 8 or pyruvate kinase, 9 has been shown to increase apoptosis, decrease proliferation and tumor growth. Dichloroacetate (DCA), a small molecule that inhibits PDK (thus activating pyruvate dehydrogenase (PDH), the gatekeeper of GO) decreases tumor growth in many cancers including non-small cell lung, 7 pancreatic, 10 metastatic breast, 11 colon, 12 prostate, 13 endometrial, 14 ovarian cancer 15 and neuroblastoma. 16 Importantly, preliminary data from a small human trial showed that DCA may hold promise in patients with advanced recurrent glioblastoma multiforme (GBM). 17 Activation of the master regulator of angiogenesis hypoxiainducible factor 1a (HIF1a) results in suppression of mitochondrial function and upregulation of glycolysis, [18] [19] [20] but there is also emerging evidence that activation of mitochondrial signaling can directly inhibit HIF1a in a feed forward manner. For example, inhibition of PDK can inhibit HIF1a in cancer cells, although the mechanism has not been systematically explored. 21 Mitochondria may regulate HIF1a via a number of ways including (a) direct effects of mitochondria-derived reactive oxygen species(mROS) like H 2 O 2 on redox-sensitive units of HIF1a [22] [23] [24] or prolylhydroxylases (PHDs), which hydroxylate HIF1a and signal it for ubiquination and degradation 18, 25, 26 ; (b) direct effects of the mitochondria-derived metabolite a-ketoglutarate (aKG), a required co-factor for the HIF1a degradation by PHDs 27 ; and (c) indirect effects mediated by a redox-and glycogen synthase kinase 3b (GSK3b)-mediated activation of p53, [28] [29] [30] [31] a known inhibitor of HIF1a signaling.
treatment (compared with the tumors of the same patients before DCA treatment) were unexpectedly less hemorrhagic and less vascular. 17 Furthermore, it is clear from the many studies that have now reported anti-tumor effects of DCA that its effects on cancer cells in vitro in terms of apoptosis are modest, while more robust effects are observed in vivo, 36 suggesting additional effects, like a potential primary inhibition of angiogenesis. Thus, we hypothesized that metabolic targeting with either molecular or pharmacologic inhibition of PDK, resulting in the reversal of the Warburg effect, can also have primary anti-angiogenic effects via a mitochondria-mediated inhibition of HIF1a, further increasing the promise of this new family of cancer therapies.
RESULTS

DCA reduces tumor vascularity and perfusion and inhibits HIF1a in vivo
We randomized athymic rats to receive either DCA orally or vehicle (water) one month after the subcutaneous injection of A549 non-small cell lung cancer (nSCLC) cells, when tumors become measurable. DCA increased survival significantly, causing a sustained decrease in tumor growth during a 9-month follow-up period ( Figure 1a ). DCA-treated animals had smaller tumors with decreased cell density and vascularization, compared with tumors from vehicle-treated animals, which were large and wellvascularized, even upon macroscopic examination ( Figure 1a) .
We quantified the DCA-induced effects in tumor perfusion with two clinically used techniques: radioisotope sestamibi-Tc99 m imaging using a micro-SPECT-PET-CT and micro-bubble contrastenhanced ultrasound perfusion imaging. DCA-treated rats had tumors with decreased sestamibi-Tc99 m uptake and micro-bubble perfusion, compared with vehicle-treated controls (Figures 1b and  c) . We also quantified the vascular density of perfused tumors by intravenous injection of an endothelium-specific lectin (ricinus communis agglutinin) before euthanasia. Lectin co-localized with the endothelial marker von-Willebrand factor (vWF) (Supplementary Figure 1a ). The tumor vessel density was decreased in the DCA-treated animals compared with the vehicle-treated controls (Figure 1d ). The decrease in the amount of tumor microvessels in the DCA-treated rats was associated with a suppression of HIF1a within the tumor cells (Figure 1e ). This was shown by the decrease of HIF1a mRNA, compared with control rats, in which abundant HIF1a was localized within the nucleus.
To assess the effects of DCA on a more aggressive tumor model, we injected rats with CRL-2335 mammary carcinoma cells, a cell line that has low expression of p53 37 ( Supplementary Figure 1b) . When injected with the same number of cells, these animals developed larger tumors at a faster rate compared with nSCLC cells, but DCA decreased both the size and the vascularity of these tumors as well ( Supplementary Figures 1c and d) .
Activation of PDH increases mitochondrial function and inhibits HIF1a
To assess mitochondrial function in vivo, we measured mitochondrial membrane potential and mROS in tumor tissues immediately after resection, as described previously. 17 The generation of the negative potential across the mitochondrial membranes (that is, the export of hydrogen cations as electrons are donated to the electron transport chain) is linked to respiration and can be used as a surrogate for mitochondrial function. Mitochondrial hyperpolarization is associated with a decrease in the production of mROS (that is, superoxide) and resistance to apoptosis, because it promotes a closure of the redox-and voltage-sensitive mitochondrial transition pore, through which pro-apoptotic mediators efflux to the cytoplasm. 38 Thus, it is not surprising that most solid tumors have more hyperpolarized mitochondria compared with non-cancerous tissues. 7, 39 DCA-treated nSCLC tumors had decreased mitochondrial membrane potential (measured by TMRM, a mitochondria-selective voltage-sensitive rhodamine-based dye) and increased mROS (that is, mitochondrial superoxide measured by MitoSOX) compared with controls ( Figures 2a and b) . These data show that the mitochondrial effects of DCA, previously shown in short-term in vivo models, are sustained in a long-term model and parallel the decrease in tumor angiogenesis in vivo. Importantly, these effects were associated with an increase in PDH activity measured by two separate techniques ( Figure 2c ). As predicted, the increase in PDH activity, and thus the increase in the entry of pyruvate into the mitochondria, caused an increase in nSCLC cell respiration in both whole-cell ( Figure 2d ) and mitochondria preparations ( þ 28% ± 3.5%, n ¼ 5; Po0.05). Furthermore, in keeping with the increase in mitochondrial superoxide, DCA increased both intracellular and extracellular nSCLC H 2 O 2 levels (Figure 2e ). H 2 O 2 has a longer effective diffusible radius that (in contrast to superoxide) allows it to reach extra-mitochondrial redox-sensitive targets. The superoxide dismutase inhibitor (SODi) diethyl-dithio-carbamate 40 eliminated most of the H 2 O 2 , suggesting that it is mostly derived from superoxide ( Figure 2e ). DCA also increased the activity of the Krebs' cycle enzyme isocitrate dehydrogenase (IDH) and levels of its product a-ketoglutarate (aKG) (Figure 2f ). These results were reproduced in the CRL-2335, mammary carcinoma cells, where DCA decreased mitochondrial membrane potential and increased mROS, PDH activity, mitochondrial respiration, H 2 O 2 (in an SODdependent manner), IDH activity and aKG levels (Supplementary Figure 2) .
The increase in aKG levels was associated with increased prolylhydroxylase (PHD) activity in DCA-treated nSCLC cells shown by both immunofluorescence and immunoblots with an antibody against hydroxylated HIF1a (Supplementary Figures 3a and b) . This was associated with decreased nuclear levels of HIF1a in DCAtreated nSCLC cells (Supplementary Figure 3c) . In addition, a cellpermeable form of aKG (octyl-aKG, 0.01-0.1 mM) mimicked DCA and decreased nuclear levels of HIF1a (Supplementary Figure 3c) . The DCA-induced decrease in nuclear HIF1a levels was also observed in mammary carcinoma cells (Supplementary Figure 3d) .
To confirm the decrease in HIF1a levels observed in vivo in Figure 1e , we treated nSCLC cells with DCA and detected a small but significant decrease in HIF1a protein levels at 12 and 24 h after treatment (Figure 3a ). In addition, DCA decreased HIF1a mRNA levels in nSCLC cells in vitro (Supplementary Figure 4) . In a separate experiment, we treated nSCLC cells with DCA in the presence of the 20S proteasome inhibitor MG132 and showed that the DCA-induced decrease in HIF1a protein levels was mostly negated by MG132 (Figure 3a) , suggesting that DCA promotes HIF1a degradation pathways.
We then treated nSCLCs with an adenovirus carrying a wellstudied mutated form of HIF1a (CA5), which is resistant to proline hydroxylation and proteosomal degradation. 41 Because AdCA5 encodes an altered form of human HIF1a with deletion of amino acids 392-520, we can separate endogenous HIF1a from CA5 using immunoblots and an antibody to HIF1a that recognizes amino acids 610-727. 42 Although DCA decreased endogenous HIF1a protein levels, DCA did not decrease the CA5 mutant form of HIF1a (Figure 3b) , suggesting that the primary effects of DCA on HIF1a-mediated degradation are through PHDs.
We then measured the effects of DCA on HIF1a activity by using a standard dual-luciferase reporter assay. Because we would be unable to separate the effects of DCA between endogenous and the CA5 form of HIF1a in terms of HIF1a transcriptional activity, we did not use the AdCA5 but instead treated nSCLCs with two different PHD inhibitors, dimethyloxalyglycine N-(methoxyoxoacety)-glycine methylester (DMOG) and cobalt chloride. 43 DMOG inhibits the aKG-binding site on PHDs, while cobalt chloride inhibits PHDs by displacing Fe(II) from the catalytic center. 20, 44 Inhibition of PDKII suppress cancer angiogenesis G Sutendra et al DMOG and cobalt chloride further increased HIF1a activity in nSCLCs, suggesting that PHD activity is not maximally suppressed in this cancer cell line; but addition of DCA partially decreased HIF1a activity in both, although not to the level of DCA-treated control nSCLC cells (Figure 3c ). This suggests that DCA has additional effects on HIF1a transcriptional activity, independent of its effects on PHD-dependent degradation of HIF1a.
We then treated nSCLC cells with a PDKII and a PDHE1a short interfering RNA (siRNA) (the target for PDKII) and effectively inhibited the expression of both enzymes (Supplementary Figure 5a) . PDKII siRNA-treated cells had decreased HIF1a activity (using the HIF1a-specific luciferase construct) and nuclear protein similar to the levels caused by DCA, with no additional inhibition seen with DCA ( Figure 3d and Supplementary Figure 5b) . PDHE1a siRNA-treated nSCLC cells did not show any increase in nuclear HIF1a and activity, suggesting that PDH is maximally inhibited in this cell line, but were completely resistant to DCA (Figure 3d and Supplementary Figure 5b) . On the other hand, PDHE1a siRNA treatment of normal small airway epithelial cells (SAECs), where PDH activity may not be inhibited like in cancer, caused an increase in HIF1a activity and nuclear levels ( Figure 3e and Supplementary Figures 5c and d) .
N-Acetylcysteine (NAC) is an antioxidant that has recently been shown to inhibit HIF1a activity in a PHD-dependent manner. 45 NAC did not completely reverse the increase in mROS by DCA in nSCLCs, suggesting that this antioxidant may not be as important in regulating mROS as it is in decreasing cytoplasm-derived ROS (Supplementary Figure 6a) . Similar to the work by Gao et al., 45 NAC decreased HIF1a activity in nSCLCs, while the addition of DCA further decreased HIF1a activity (Supplementary Figure 6b) . Again, the further decrease in HIF1a activity suggests that DCA is inhibiting HIF1a transcriptional activity in addition to its effects on PHD-dependent HIF1a degradation.
DCA increases p53 and GSK3b-mediated inhibition of HIF1a p53 is redox-sensitive [28] [29] [30] and has been shown to degrade HIF1a in a PHD-independent manner 35 and inhibit HIF1a transcriptional activity. 32, 33 DCA increased p53-activity (shown by a p53-specific luciferase assay) and nuclear localization in nSCLC cells and this was prevented by an SODi and mimicked by exogenous H 2 O 2 ( Figures 4a and b) . In addition, DCA increased p53 nuclear localization in vivo (Figure 4b ). The increase in p53 activity was supported by the increase in the p53-target gene product p21 in vitro and in vivo (Figures 4b and c) . p21 is a cyclin-dependent kinase inhibitor and can halt proliferation by locking cells in the G0/G1 phase, an effect that may contribute to the antiproliferative properties of DCA in nSCLC cells, as shown by a decrease in the percentage of cells expressing proliferating cell nuclear antigen (PCNA) (Figure 4d ). In addition, DCA increased p53 activity and nuclear localization, increased p21 protein and mRNA levels and decreased proliferation in the CRL-2335 mammary carcinoma cells as well (Supplementary Figures 7a-c) .
Glycogen synthase kinase-3b (GSK3b) is a metabolic kinase that is inhibited in the glycolytic environment of cancer 46, 47 or pulmonary hypertension 48 and has been shown to activate p53 31 and inhibit HIF1a. 49 DCA increased GSK3b activity in nSCLC and mammary carcinoma cells in vitro (in a dosedependent manner) and in nSCLC tumors in vivo (Figure 5a and Supplementary Figures 8a and b) . Thus, GSK3b activation may also contribute to the DCA-mediated activation of p53 and inhibition of HIF1a.
These effects of DCA were also present in GBM cells, derived from a patient with a new diagnosis of advanced GBM at the time of his initial surgery. DCA increased H 2 O 2 levels, IDH activity and aKG levels, similar to nSCLC and mammary carcinoma cells, although the effects on IDH activity and aKG levels were more robust in GBM cells compared with the other two cancers (Supplementary Figure 9a) . Once again, DCA decreased nuclear levels of HIF1a, increased p53 activity, increased p21 protein and messenger RNA (mRNA) levels and decreased proliferation ( Supplementary Figures 9b-e) . DCA-induced activation of PDH decreases glucose transporter expression and glucose uptake The mRNA levels of several glucose transporters (GLUTs) and VEGF, all gene products of HIF1a were decreased in DCA-treated nSCLCs in vitro and in vivo (Figure 5b ). To assess the functional consequences of the decrease in GLUTs expression, we measured radiolabeled glucose transport. DCA decreased functional glucose transport in nSCLC and mammary carcinoma cells in vitro, with the later being more pronounced (Figure 5b and Supplementary Figure 10) . Furthermore, tumor fluoro-deoxy-glucose (FDG) uptake, measured by positron emission tomography (PET) using a micro-SPECT-PET-CT, was decreased in the nSCLC DCA-treated rats (Figure 5c ).
DCA decreases the recruitment of bone marrow-derived angiogenic cells In addition to VEGF, 50, 51 HIF1a activation results in increased expression of stromal-derived factor 1 (SDF1), 52 a signaling chemokine involved in the recruitment of bone marrow-derived angiogenic cells to ischemic tissues 53 and tumors. 54 Recruitment of these cells to tumors contributes to angiogenesis, because these cells (as well as other inflammatory cells) can differentiate into tumor-associated cells (for example tumor-associated fibroblasts 55 ), which can be additional sources of angiogenic factors. 56 DCA decreased SDF1 levels within nSCLC cells both in vitro and in vivo (Figure 6a ) and decreased SDF1 and VEGF levels in the media of nSCLC cells in a dose-dependent manner (Figure 6b ).
We then isolated and characterized rat bone marrow-derived mesenchymal stem cells (BMDMSC) based on currently proposed criteria 57 in terms of surface markers (CD-73, -90 and -105 positive and CD-14, -19, -31 and -34 negative), plastic adherence and differentiation potential (for example, to osteocytes) ( Supplementary  Figures 11a and b) . In addition, BMDMSCs also express cKit 58, 59 and CXCR4, the receptor for SDF1. 60 To determine whether DCA decreases the recruitment of BMDMSCs in vitro, we plated BMDMSCs in the top insert of a Boyden-Chamber assay and the supernatant from vehicle-treated versus DCA-treated nSCLC cells in the bottom insert. DCA decreased the migration of BMDMSC in a dose-dependent manner (Figure 6c ). The effect of DCA on BMDMSC was strictly on cell migration, as DCA did not induce apoptosis in these cells (Supplementary Figure 11c) . In vivo, DCA-treated nSCLC tumors had a decrease in SDF1 as well as cKit levels (Figure 6d ), in agreement with a decrease in cKit þ -cells infiltrating the tumors (Figure 6e ). These data are in keeping with a recent report implicating SDF1 in the homing of cKit þ stem cells to ischemic tissues. 61 To confirm that the cKit þ -cells had migrated from the rat bone marrow into the human xenotransplant tumor, we double stained them with an anti-rat antibody. The recruitment of rat cKit þ -cells was evident mostly in areas around blood vessels in the vehicletreated nSCLC tumors (Figure 6e and Supplementary Figure 11d Inhibition of PDKII suppress cancer angiogenesis G Sutendra et al formation using a matrigel assay. Compared with normoxic noncancer-induced control medium, hypoxic (pO 2 B30 mm Hg) noncancer-induced medium increased angiogenesis, as hypoxia is a direct signal for angiogenesis (Figure 7a ). The supernatant of normoxic untreated nSCLC cells and mammary carcinoma cells (cancer-induced media) increased angiogenesis to a level similar to the hypoxic medium, reflecting the importance of the pseudohypoxic activation of HIF1a in cancer cells (Figure 7a ). In addition, the supernatant from DCA-treated nSCLC and mammary carcinoma cells returned angiogenesis to levels comparable to noncancer induced control medium (Figure 7a ).
DISCUSSION
Here, we describe a metabolic strategy for inhibiting cancer angiogenesis. We extend the growing evidence that metabolic modulators can promote apoptosis in cancer cells directly, to a paradigm in which they can have additional beneficial effects, limiting tumor angiogenesis. It is well established that HIF1a activation in cancer can induce many of the metabolic signatures of cancer, including the Warburg effect. However, although there is emerging evidence that mitochondria signaling can directly activate HIF1a in a feed forward manner, 21 perhaps contributing to the normoxic activation of HIF1a in cancer, the potential effects of mitochondria-targeting drugs on tumor angiogenesis have not been studied. Given the momentum that the metabolic theory of cancer is gaining and the interest in developing metabolic modulators as cancer therapies, our work may be important in translational cancer research and therapeutics.
Suppressed GO/Gly ratio and mitochondrial hyperpolarization are partially reversible in cancer cells and contribute to a resistance to apoptosis. 7, 17 Mitochondrial hyperpolarization and a decrease in GO/Gly ratio seem to also be critical events in the mitochondrial response to hypoxia in oxygen-sensitive tissues like the pulmonary arteries. 48 We have recently shown that the cause for this mitochondrial hyperpolarization and PDH inhibition in hypoxia-exposed pulmonary arteries was a disruption of the 'mitochondria-endoplasmic reticulum unit', resulting in a decrease in intra-mitochondrial calcium and a subsequent decrease in the activity of PDH, a calcium-dependent enzyme. 62 Inhibition of PDH, GO and their downstream mitochondrial signaling can lead to HIF1a activation in the oxygen-sensitive pulmonary circulation. Forced or sustained activation of PDH and GO during hypoxia prevents hypoxic signaling: the mitochondria do not hyperpolarize, mROS do not decrease, HIF1a is not activated and the acute and chronic response to hypoxia (that is, pulmonary hypertension) are absent in the pulmonary circulation. 48 It is unknown whether a similar disruption of the 'mitochondriaendoplasmic reticulum unit' that could support a decrease in PDH function also occurs in cancer. There are however, examples of very vascular tumors like paragangliomas 63 or renal cell carcinomas, 64 which result from disruption of GO and mitochondrial signaling due to loss-of-function mutations in mitochondrial enzymes. It remains to be determined whether PDH may also be genetically abnormal in some vascular tumors. Certainly, if a suppression of GO can occur in a cancer cell during normoxia (for example, by primary inhibition of PDH), pseudohypoxic signaling could be initiated, leading to HIF1a activation and angiogenesis, initiating a positively reinforcing feedback loop with further suppression of mitochondrial function by HIF1a.
The DCA-induced increase in aKG and H 2 O 2 that we describe can inhibit HIF1a activity in both a PHD-dependent and -independent manner (Figure 7b ), as our experiments with cobalt chloride or DMOG-treated cells show (Figure 3c ).
PHD-dependent HIF1a degradation
aKG is a cofactor in the PHD-dependent hydroxylation and degradation of HIF1a. 27 In conditions that aKG production may be suppressed (for example, because of a functional suppression of mitochondria), the tonic PHD-dependent inhibition of HIF1a that occurs in normoxic conditions may be inhibited. Therefore, a DCAinduced restoration of aKG levels may promote PHD-dependent HIF1a inhibition, as we show with the increase in HIF1a hydroxylation ( Supplementary Figures 3a and b) .
However, several papers in the literature suggest that H 2 O 2 (and other oxidative signals) inhibits PHD activity, stabilizing HIF1a. 25, 26 Thus, the decrease in H 2 O 2 levels that is associated with suppressed mitochondrial function would be predicted to activate PHD and inhibit HIF1a, and in such a case, a DCAinduced increase in H 2 O 2 would promote HIF1a stabilization, in contrast to our findings. [28] [29] [30] and to promote HIF1a ubiquination and degradation via a PHD-independent mechanism, 34, 35 (c) the increase in p53 activity can also indirectly decrease HIF1a transcriptional activity as p53 and HIF1a compete for a common co-transcription factor, that is, p300 32 and (d) an increase in GSK3b activity, which is known to occur in conditions of normal metabolism (and is inhibited in glycolytic environments like those in cancer or pulmonary hypertension [46] [47] [48] 65 ) is known to both activate p53 31 and directly inhibit HIF1a. 49, 66 We provide strong evidence that DCA normalizes the metabolic remodeling in cancer by promoting GO and normalizing the suppressed metabolic-mitochondrial signals that may activate HIF1a in cancer cells, even in normoxia. We also (e) Immunohistochemistry and quadruple staining identify the presence of recruited cKit þ rat cells (staining positive for an anti-rat antibody) near the vessels of the human nSCLC xenotransplant control tumors, but not in DCA-treated tumors (vessels stained green by lectin; rat cells are shown in red using an anti-rat antibody, cKit is purple; nuclear stain DAPI is blue).
show that DCA increases p53 activity in an H 2 O 2 -dependent manner and GSK3b activity. In summary, these mechanisms support a PHD-independent activation of HIF1a as well as an aKGbased PHD-dependent activation of HIF1a in the normoxic cancer cells, which were reversed by DCA (Figure 7b) .
In hypoxic normal cells, an mROS (H 2 O 2 )-dependent PHD inhibition may drive HIF1a activation, but this mechanism may be less relevant to normoxic activation of HIF1a in cancer cells. Although we did not study hypoxic signaling, our data and the literature suggest that this mitochondria-HIF1a axis maybe regulated differently between pathologic normoxic conditions (that is, cancer) and physiologic hypoxic conditions. 18, 66 The multitude of mechanisms suggests that a) the final result on HIF1a transcriptional activity may be a balance of different and even opposing signals at any given time, and b) diversity in the mitochondria-HIF1a signaling among tissues and conditions or among different cancers is also possible.
Although we observed a significant decrease in HIF1a mRNA levels in our in vivo models, the decrease in mRNA levels in vitro was modest. In addition, our experiment with the proteosome inhibitor MG132 preventing most of the effects of DCA-mediated decreases in HIF1a protein levels (Figure 3a) suggests that in vitro, the effects of DCA on HIF1a levels are driven mostly by an increase in its degradation rather than by a decrease in its mRNA levels. The differences between the mRNA levels of HIF1a after DCA treatment in vivo and in vitro may be due to (a) the fact that these In cancer (at least in several solid tumors), the mitochondria-based GO and respiration are decreased, in part due to inhibition of pyruvate dehydrogenase (PDH) activity. Resulting pseudo-hypoxic signals from mitochondria can contribute to a 'feed forward' HIF1a activation, which in turn increases PDK expression, inhibiting PDH and closing a feedback loop that causes a sustained glycolytic environment. DCA activates PDH by inhibiting PDK. Increased PDH activity reverses the pseudo-hypoxic signals by increasing mROS, including H 2 O 2 , and Krebs' cycle substrates (that is, a-ketoglutarate; aKG). The increase in aKG results in activation of prolyl-hydroxylases (PHD), while the increase in H 2 O 2 results in activation of p53 and direct inhibition of HIF1a transcriptional activity. Activation of p53 results in HIF1a degradation and decreased transcriptional activity, independent of PHDs and H 2 O 2 . Inhibition of HIF1a, results in decreased recruitment of bone-marrow derived mesenchymal stem cells (BMDMSC) and decreased tumor angiogenesis and perfusion. Under certain conditions, H 2 O 2 could inhibit PHDs, resulting in HIF1a stabilization (see discussion).
animals were treated with DCA for several months whereas, in our in vitro studies, DCA treatment was for 12 h, and (b) the differences between the in vivo conditions of a tumor that cannot be recapitulated in vitro; specifically, the studied material from the tumors included many non-cancer cells, like inflammatory or angiogenic circulating cells, in which the mechanisms for HIF1a expression regulation may be different than in cancer cells. For example, a recent report showed that the HIF promoter region does contain a HIF1a-binding site, suggesting that HIF1a may be able to regulate its own expression. 67 Therefore, the decrease in HIF1a mRNA by DCA may be an extension of its direct inhibition on HIF1a transcriptional activity. In summary, while the early and direct effects of DCA on HIF1a levels are due to an increase in its degradation, the chronic effects of DCA may include an additional decrease in its transcription.
Several downstream targets of HIF1a were decreased in DCAtreated cells confirming the effectiveness of this anti-angiogenic strategy, including glucose transporters, VEGF and SDF1. Direct effects on angiogenesis were shown in vitro and effective inhibition of angiogenesis in vivo was shown with several techniques. We also provided evidence that the inhibition of SDF1 could contribute to decreased recruitment of stem cells within the tumor, although more work is needed to determine the relative importance of this mechanism in different cancer models.
Along with recent publications by others, our work suggests that positively reinforced feedback loops exist between inhibition of GO and activation of HIF1a. While we show that the decrease in GO leads to HIF1a activation, others have shown that HIF1a activation inhibits mitochondria enzymes that would further suppress GO. Specifically, strong evidence exists that HIF1a increases the expression of PDK1 68, 69 and pyruvate kinase M2 (PKM2). 70 Such positively reinforcing feedback loops underlie not only the importance of this mechanism for the survival of tumors, but also the difficulty of its therapeutic targeting.
Nevertheless, the inhibition of angiogenesis by a metabolic modulator like DCA (or other potential inhibitors of PDK or pyruvate kinase isoforms) may prove to be more attractive than VEGF inhibitors. This is because the signaling pathway is inhibited more proximally, at the level of oxygen sensors like the mitochondria. This may allow less opportunity for tumors to escape, as is often the case with VEGF inhibitors. The persistent activation of HIF and other pro-angiogenic factors allows for recruitment of other pathways, including the attraction of bone marrow or circulating pro-angiogenic cells within the tumors, and eventual resistance to VEGF inhibition. 71 Reversing the original pseudo-hypoxic signals from the mitochondria may be a logical alternative approach to inhibit angiogenesis. In addition, this approach may provide more tumor selectivity. Although direct inhibition of HIF1a or VEGF may adversely affect many physiologic or regenerative functions requiring appropriate activation of this pathway, reversal of the primary pseudo-hypoxic signal may restrict the effects to the tissues where this is primarily taking place, that is, the tumors. It is important to remember that HIF1a can be activated by mild hypoxia, not enough to inhibit mitochondrial function. 18 However, severe hypoxia/anoxia or primary deficiencies in mitochondrial enzymes will cause a suppression of GO, inducing the signals that we discuss above. Thus, DCA, by reversing this mitochondrial suppression, may preferentially affect tumors and not interfere with the HIF1a signaling in physiologic conditions (that is, wound healing, erythropoietin activation, and so on). In keeping with this concept, the GBM patients treated with DCA showed decrease in tumor vascularity, but after many months of therapy, did not develop anemia or wound-healing abnormalities. 17 At the same time, such approaches, that is, targeting mitochondrial enzymes, may allow the tumor to eventually express alternate isoforms of these enzymes, perhaps less sensitive to these drugs. For example, there are four isoforms of PDK, all with variable sensitivities to DCA, with PDKII being the most sensitive. 72 Very recently, PDKII and DCA were crystallized together revealing molecular interactions that explain the relatively specific inhibition of PDKII by DCA. 73, 74 Our data using siRNA to inhibit PDKII and PDH in this and our previous work 7 support the fact that DCA works primarily by inhibition of PDKII. It is possible, however, that after chronic DCA therapy PDKII may be downregulated, or compensated by PDK isoforms that are less sensitive to DCA. Another mechanism of potential resistance maybe the recently reported decrease of the DCA transporter SLC5A8, via methylation, is cancer tissues. 75 Babu et al. reversed this by increasing the expression of SLC5A8 with the DNA methylation inhibitor 5 0 -Azadc, potentiating the anticancer effects of DCA. The fact that the effects of DCA were sustained in our xenotransplant nSCLC model for 9 months is reassuring (we had previously shown tumor regression in short-term, 3-4-week, studies in xenotransplant models, without exploring any effects on angiogenesis 7 ), but chronic and large studies in humans will be needed to address this potential concern.
In summary, the ability of metabolic modulators to suppress several mitochondria-driven paracrine pro-angiogenic pathways, in addition to their direct effects on apoptosis of the tumor cells, may open a new window in the rapidly expanding chapter of metabolic modulators in cancer therapy.
MATERIALS AND METHODS
The University of Alberta Animal Ethics Committee approved all animal experiments.
Cell culture conditions, cell lines, confocal imaging Immunobloting, qRT-PCR, commercially available ELISAs for VEGF and SDF, Hydrogen Peroxide Assay, PDH activity assays, IDH activity assay, a-ketogultarate assay, mitochondrial and whole cell respiration assays, mesencheymal stem cell isolation, culture and characterization. See Supplement information.
In vivo tumorigenicity assays
A cell suspension of non-small cell lung cancer (A549) or mammary carcinoma cells (CRL-2335) in growth media (3 Â 10 6 cells per injection) was injected subcutaneously into nude athymic rats. Rats were divided into controls (water) and DCA-treatment groups (DCA 0.070 g/l in drinking water) at one month for non-small cell lung cancer and 10 days for mammary carcinoma, post tumor cell injection, a time at which tumors become clearly measurable. Endpoints were mortality or severe morbidity due to very large tumors, requiring euthanasia, based on pre-specified standard criteria by our animal ethics committee. By measuring the amount of water consumed, we calculated and adjusted the concentration of DCA required to achieve a daily dose similar to that used clinically (50 mg/kg), as previously described. 7 Rats were observed weekly for the appearance of tumors at injection sites, and tumor size was measured weekly with calipers by measuring the maximum length and width to assess tumor area (mm 2 ).
Positron emission tomography (PET) imaging
Glucose uptake was imaged in vivo in rats anesthetized using isoflurane gas anesthesia (20% oxygen) using FDG as a radiotracer. PET imaging was performed using a Triumph PET/SPECT/CT system (, Northridge, CA, USA). Rats were injected with 500 uCi of FDG and imaged 60 min after FDG injection. PET data acquisition images are shown using a pseudocolor map (red ¼ high glucose uptake). Data were quantified as mean PET signal by segmentation of the tumor using computed tomography (CT).
SPECT imaging
SPECT imaging was performed using a Triumph PET/SPECT/CT system (GE Healthcare). Rats were injected with 5 mCi of Tc-99-sestamibi under isoflurane gas anesthesia (20% oxygen) and imaged immediately after radioisotope injection. SPECT data acquisition images are shown using a pseudocolor map (red indicates increased perfusion). Tumors were excised Inhibition of PDKII suppress cancer angiogenesis G Sutendra et al from animals and Tc-99-sestamibi was directly measured using a Tc-99 m radioisotope detector.
Lectin perfusion assay
Rats were anesthetized, heparinized using 1000 IU/kg of heparin (American Pharmaceuticals Partners, Schaumbert, IL, USA) and injected with 5 mg of FITC-conjugated Ricinus Communis Agglutinin I (Vector Laboratories, Burlinghame, CA, USA) in the jugular vein. After circulation of lectin for 20 min, the rats were euthanized and the tumor tissue was harvested.
Tissue was sliced 5 mm thick and fixed in 4% paraformaldehyde and imaged using confocal microscropy. Lectin signal was quantified using Ziess software and displayed as arbitrary fluorescence units (AFU).
Non-targeted micro-marker ultrasound
The VeVo 770 (Visual Sonics, Toronto, ON, Canada) imaging system with non-targeted contrast agent to assess tumor perfusion. Animals were canulated at the jugular vein and a bolus injection of 2 Â 10 9 microbubbles/ml was administered. Data acquisition of tumor perfusion was initiated 20 frames before the bolus injection and data were continuously acquired for an additional 780 frames. Maximum perfusion was quantified in the tumor by Visual Sonics Imaging Software, which calculates the maximum amount of contrast agent detected over the full 800 frames.
Adenoviral infection
Non-small cell lung cancer cells were grown on T75 flasks (Sigma-Aldrich, Oakville, ON, Canada) and infected with AdCA5 (a generous gift from Dr Gregg Semenza) at a multiplicity of infection of 150 in serum-free DMEM (Gibco, Invitrogen, Burlington, ON, Canada) for 6 h allowing an infection rate of B50%. Medium was then exchanged for F12K containing 10% FBS.
Matrigel assay
Matrigel (BD Biosciences, San Jose, CA, USA) was prepared as a 1:1 mixture with serum free, supplemented Medium 200 (Cascade Biologics, Portland, OR, USA) and plated (300 ml per well) on a 24-well dish. Once the matrigel had solidified, human aortic endothelial cells were plated at 60 000 cells/ well.
Synthesis of a-ketoglutarate derivative
Cell-permeable a-ketoglutarate was synthesized as previously described. 27 The octyl-a-ketoglutarate ester was prepared as follows: octylchloroformate was added drop by drop to a-ketoglutaric acid (10 mmol) and triethylamine (1.0 eq) in dichloromethane (50 ml). The mixture was stirred at room temperature for 16 h and diluted with dichloromethane (50 ml), washed with 0.5 N aqueous HCl (50 ml) and dried. Octyl-aketoglutarate ester was prepared to 498% purity as assessed by gas chromatography.
Cell migration assay
Cell migration assay was performed according to protocol using the CHEMICON QCM TM 24-well Migration Assay (Millipore, Billerica, MA, USA). MSCs (1 Â 10 6 cells per ml); also see supplement.
Glucose transport
Cancer cells were grown to confluence in 12-well dishes and treated with DCA (0.5 mM) for 4 days. Two hours before performing radioactive flux studies the media was removed, the cells washed twice with glucose-free Krebs-Ringer's Solution (120 mM NaCl, 25 mM NaHCO 3 , 4 mM KCl, 1. . The cells were then lysed by adding 500 ml of 5% trichloracetic acid and placed on a shaker table overnight. Next, three 150 ml samples from each well were added to 4 ml of ScintiSafe liquid scintillation fluid (Fisher, Toronto, ON, Canada) in scintillation vials. The vials were then placed in a Beckman LS 6500 multi-purpose liquid scintillation counter for quantification. All radioactivity was normalized to standards and corrected for background levels of isotope.
HIF1a and p53 luciferase assays
HIF1a and p53 dual-luciferase reporter kits (SA Biosciences, Mississauga, ON, Canada) were used to assess HIF1a and p53 activity in nSCLC and mammary carcinoma cells as described in the commercially available protocols. Briefly, cells (10 000 cells/well) were plated on a 96-well plate containing the transfection agent (Xfect; CloneTech, Mountain View, CA, USA) and the HIF1a and p53 Cignal reporter (which contained a control Renilla reporter as well). After 16 h of transfection, the transfection media was replaced with regular growth media and exposed to treatment for 48 h. HIF1a and p53 activity was assessed using the Promega dual luciferase reporter assay system from Promega (SA Biosciences Cells were lysed with the passive lysis buffer (provided in the kit) before luminescence was detected with a illuminometer. HIF1a and p53 activity was standardized to the transfection of each cell by normalizing data to Renilla luminescence.
siRNA treatment
Non-small cell lung cancer cells and SAECs were grown to 80% confluence in 96-well culture-plates and confocal dishes. The transfection agent siPORTamine (Ambion siRNA Transfection II kit 1631, Ambion, Faster city, CA, USA) was pre-incubated at room temperature for 10 min at a ratio of 1:12 in OptiMEM1 culture medium (Invitrogen-GIBCO) before being mixed with 50 nM PDKII or PDHE1a siRNA (Ambion) or scrambled RNA (Ambion). The culture media was aspirated from the cells, and the transfection agent-RNA complex mixture was allowed to spread over the monolayer of cells.
Plates were incubated at 37 1C for 48 h.
Statistics
We used unpaired two sample t tests for before and after DCA comparisons and ANOVA with post hoc analysis (Tukey's test) for comparisons among three or more groups and Kaplan Meier for survival studies using standard SPSS software (Statview 4.02, SAS Institute, Cary, NC, USA). Data are presented as mean ± s.e.m. and Po0.05 was considered significant.
